Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 5/20 | 0.32 |
| ▸ | RAF1 | P04049 | 4/20 | 0.32 |
| ▸ | CDK4 | P11802 | 2/20 | 0.32 |
| ▸ | CCND1 | P24385 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL595975 | 0.87 | KDM4C (0.32) | CDK4CCND1KDM4C | |
| SCHEMBL1336738 | 0.86 | SCN9A (0.39) | SCN9ABRAFRAF1CCND1IRAK1 | |
| SCHEMBL391680 | 0.81 | SCN9A (0.38) | SCN9ABRAFRAF1CDK4CCND1 | |
| SCHEMBL394212 | 0.80 | SCN9A (0.38) | SCN9ABRAFRAF1CDK4CCND1 | |
| SCHEMBL1339001 | 0.80 | SCN9A (0.37) | SCN9ABRAFRAF1CDK4CCND1 | |
| SCHEMBL392585 | 0.80 | SCN9A (0.39) | SCN9ABRAFRAF1CDK4CCND1 | |
| SCHEMBL1337981 | 0.80 | SCN9A (0.37) | SCN9ABRAFRAF1CDK4CCND1 | |
| SCHEMBL1338497 | 0.79 | SCN9A (0.36) | SCN9ABRAFRAF1CDK4CCND1 | |
| SCHEMBL391784 | 0.79 | SCN9A (0.37) | SCN9ABRAFRAF1CDK4CCND1 | |
| SCHEMBL1338102 | 0.78 | IRAK1 (0.38) | SCN9ABRAFRAF1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063212-B2 | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | ELI LILLY AND COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2125794-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, AURKC, BUB1B | SCN9A 3850/4885BRAF 1939/4885RAF1 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.